# Study of REOLYSIN® in Combination With FOLFIRI and Bevacizumab in FOLFIRI Naive Patients With KRAS Mutant Metastatic Colorectal Cancer

> **NCT01274624** · PHASE1 · COMPLETED · sponsor: **Oncolytics Biotech** · enrollment: 36 (actual)

## Conditions studied

- KRAS Mutant Metastatic Colorectal Cancer

## Interventions

- **BIOLOGICAL:** REOLYSIN®
- **DRUG:** Irinotecan
- **DRUG:** Leucovorin
- **DRUG:** Fluorouracil (5-FU)
- **DRUG:** Bevacizumab

## Key facts

- **NCT ID:** NCT01274624
- **Lead sponsor:** Oncolytics Biotech
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-12
- **Primary completion:** 2018-02
- **Final completion:** 2018-11
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2018-12-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01274624

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01274624, "Study of REOLYSIN® in Combination With FOLFIRI and Bevacizumab in FOLFIRI Naive Patients With KRAS Mutant Metastatic Colorectal Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01274624. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*